PROFESS与TRANSCEND两个试验中,替米沙坦每日80毫克与安慰剂相比降低了4mmHg收缩压,但未降低一级复合心血管终点的风险。ACCOMPLISH与ALL-HAT二个在高血压临床试验中氨氯地平与利尿剂比较的结果有很大差别,原因可能是在ACCOMPLISH试验中,联合使用血管紧张素转换酶抑制剂。ACCOMPLISH试验进一步证实,氨氯地平通过平稳控制24h血压,可更有效地预防血管性并发症。 In the two trials of PROFESS and TRANSCEND, telmisartan 80 mg daily reduced systolic blood pressure by 4 mmHg compared with placebo but did not reduce the risk of primary composite cardiovascular end points. The results of two trials comparing ACCOMPLISH with ALL-HAT in hypertensive clinical trials of amlodipine and diuretics are quite different, probably due to the combination of angiotensin-converting enzyme inhibitors in the ACCOMPLISH trial. ACCOMPLISH test further confirmed that, amlodipine by a steady control of blood pressure 24h, can be more effective in preventing vascular complications.